- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Aurora Cannabis announced on Tuesday that it expects its common stock to debut on the New York Stock Exchange before the end of October.
The expansion of Canadian cannabis companies into the US public markets continues as Aurora Cannabis (TSX:ACB) officially confirmed its application for a New York Stock Exchange (NYSE) listing on Tuesday (October 9).
As the company awaits for approval from the exchange on its listing and regulatory requirements, Aurora confirmed it would employ the same ticker symbol “ACB” for its shares in the US.
“Through our NYSE listing, Aurora joins an established group of mature global brands with improved access and exposure to an engaged international institutional investor audience,” Terry Booth, CEO of Aurora, said in the press release.
Aurora will join fellow Canadian licensed producer (LP) Canopy Growth (NYSE:CGC,TSX:WEED) on the NYSE, which joined the exchange in May. The first Canadian cannabis stock to reach the a premier US exchange was Cronos Group (NASDAQ:CRON,TSX:CRON), which made its debut on the NASDAQ in February.
Shares of Aurora had already found its way to the US market by trading on the OTC Best Markets. The company confirmed once it obtains approval for its NYSE listing it would de-list its shares from the OTCQX exchange.
The company estimated its NYSE debut will occur before the end of the month.
Aurora had confirmed its intentions to pursue a US listing through its Q4 update to shareholders. It was discovered in a securities filing the cannabis company was targeting the NYSE directly.
“This listing provides access to a broader investor audience who gain the opportunity to participate in our continued success,” Booth said as part of the quarterly report.
This update was given when rumors circulated that Aurora was a top candidate to get a partnership with The Coca-Cola Company (NYSE:KO) for the development of cannabis infused beverages.
During a call with investors Cam Battley, chief corporate office for Aurora, said getting a US listing wouldn’t “affect things immediately” in terms of the cannabis company getting a deal with a major established corporation.
Investor takeaway
Aurora’s confirmation of its NYSE listing is no surprise to the cannabis market at large, but it does provide another stepping stone of validation for the industry. Investors should be aware of the potential this new listing could bring to Aurora’s stock performance.
The company’s stock on the TSX got a boost during Tuesday’s trading session thanks to the NYSE application confirmation. As of 11:30 a.m. EST shares of Aurora were up 3.75 percent to reach C$13.29. Over a year-to-date period, its shares has increased 2.88 percent.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.